Literature DB >> 21124030

Apolipoprotein E ε4 prevalence in Alzheimer's disease patients varies across global populations: a systematic literature review and meta-analysis.

Sheila Crean1, Alex Ward, Catherine J Mercaldi, Jenna M Collins, Michael N Cook, Nicole L Baker, H Michael Arrighi.   

Abstract

BACKGROUND: The ε4 allele of apolipoprotein E (APOE) is associated with Alzheimer's disease (AD). However, attributable risk due to APOE4 varies by region and by race/ethnicity.
METHODS: A literature review and meta-analysis were conducted to estimate the prevalence of APOE4 by geographic area among AD patients.
RESULTS: Although estimates varied significantly by study design and case definition, AD patients recruited in Asian and southern European/Mediterranean communities seemed to have significantly lower E4 carrier status estimates (37 and 43%) than those recruited in North America (58%) or northern Europe (64%; all: p < 0.05).
CONCLUSIONS: APOE4 genotype frequency varies among AD patients in regional patterns similar to that of the general population. Study level differences may also contribute to the heterogeneity of published estimates of APOE4 in AD cases.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21124030     DOI: 10.1159/000321984

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  47 in total

1.  Apolipoprotein Ε ε4 frequency is increased among Chinese patients with frontotemporal dementia and Alzheimer's disease.

Authors:  Yong Ji; Mengyuan Liu; Ya Ruth Huo; Shuling Liu; Zhihong Shi; Shuai Liu; Thomas Wisniewski; Jinhuan Wang
Journal:  Dement Geriatr Cogn Disord       Date:  2013-07-23       Impact factor: 2.959

2.  APOE e4 genotype and cigarette smoking in adults with normal cognition and mild cognitive impairment: a retrospective baseline analysis of a national dataset.

Authors:  Raj K Kalapatapu; Kevin L Delucchi
Journal:  Am J Drug Alcohol Abuse       Date:  2013-06-28       Impact factor: 3.829

3.  Biomarkers of Alzheimer's disease among Mexican Americans.

Authors:  Sid E O'Bryant; Guanghua Xiao; Melissa Edwards; Michael Devous; Veer Bala Gupta; Ralph Martins; Fan Zhang; Robert Barber
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

4.  Mid-life Cardiovascular Risk Impacts Memory Function: The Framingham Offspring Study.

Authors:  Apar Gupta; Sarah R Preis; Alexa Beiser; Sherral Devine; Lisa Hankee; Sudha Seshadri; Philip A Wolf; Rhoda Au
Journal:  Alzheimer Dis Assoc Disord       Date:  2015 Apr-Jun       Impact factor: 2.703

5.  Association of the CX3CR1-V249I Variant with Neurofibrillary Pathology Progression in Late-Onset Alzheimer's Disease.

Authors:  Alan López-López; Ellen Gelpi; Diana Maria Lopategui; Jose M Vidal-Taboada
Journal:  Mol Neurobiol       Date:  2017-03-25       Impact factor: 5.590

Review 6.  Sex differences in cognitive impairment in Alzheimer's disease.

Authors:  Keith R Laws; Karen Irvine; Tim M Gale
Journal:  World J Psychiatry       Date:  2016-03-22

7.  Apolipoprotein E allelotype is associated with neuropathological findings in Alzheimer's disease.

Authors:  Neena Theresa Kumar; Knut Liestøl; Else Marit Løberg; Henrik Mikael Reims; Jan Mæhlen
Journal:  Virchows Arch       Date:  2015-04-22       Impact factor: 4.064

8.  Obsessive-compulsive disorder: a new risk factor for Alzheimer disease?

Authors:  Hela Mrabet Khiari; Afef Achouri; Nadia Ben Ali; Aroua Cherif; Hend Batti; Taieb Messaoud; Amel Mrabet
Journal:  Neurol Sci       Date:  2011-02-03       Impact factor: 3.307

9.  A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease.

Authors:  Robert C Green; Kurt D Christensen; L Adrienne Cupples; Norman R Relkin; Peter J Whitehouse; Charmaine D M Royal; Thomas O Obisesan; Robert Cook-Deegan; Erin Linnenbringer; Melissa Barber Butson; Grace-Ann Fasaye; Elana Levinson; J Scott Roberts
Journal:  Alzheimers Dement       Date:  2014-12-09       Impact factor: 21.566

10.  An updated Alzheimer's disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM.

Authors:  Daniela J Conrado; William S Denney; Danny Chen; Kaori Ito
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-08-29       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.